Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) has intracranial
activity in EGFR-mutant Non-Small Cell Lung Cancer (NSCLC). The optimal timing of brain …

Treatment for advanced non-small cell lung cancer (NSCLC) depends on the molecular
characteristics of the tumor. Mutations of the gene for the epidermal growth factor receptor …

Abstract Objective About 50–70% non-small cell lung cancer (NSCLC) patients with EGFR
mutation go through brain metastases (BM). Radiotherapy is the standard treatment before …

Background The brain is a common site for metastasis in non-small-cell lung cancer
(NSCLC). This study was designed to evaluate the relationship between the mutational of …

Introduction Osimertinib is a third‐generation tyrosine kinase inhibitor, initially approved for
epidermal growth factor receptor (EGFR) mutant non‐small cell lung cancer (NSCLC) with …

The presence of an epidermal growth factor receptor (EGFR) mutation is associated with
higher incidence of brain metastases in patients with non-small cell lung cancer (NSCLC); …

Control of non-small-cell lung cancer (NSCLC) with brain metastasis is clinically
challenging. This study retrospectively evaluated the efficacy of different adjuvant therapies …

Background This phase II, open-label study evaluated the efficacy and safety of erlotinib as
second-line therapy in non-small-cell lung cancer (NSCLC) patients with brain metastases …

Background The epidermal growth factor receptor (EGFR) mutation is a risk factor
associated with brain metastases (BMs) in patients with non‐small cell lung cancer …

Aim: To investigate the radiological features on computed tomography (CT) of brain
metastasis (BM) from epidermal growth factor receptor (EGFR)-mutated non-small cell lung …